Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07737158
NA

Venlafaxine for Non-specific Low Back Pain

Sponsor: Beijing Tiantan Hospital

View on ClinicalTrials.gov

Summary

Chronic non-specific low back pain is the leading cause of productivity loss and disability worldwide, constituting a major public health challenge. This study aims to systematically evaluate and compare the role of the antidepressant drug Venlafaxine in chronic non-specific low back pain, which is of critical importance for optimising clinical practice and developing precise, individualised treatment regimens.

Official title: Efficacy and Safety of Venlafaxine in the Treatment of Non-specific Low Back Pain

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

228

Start Date

2026-09-01

Completion Date

2028-12-30

Last Updated

2026-07-30

Healthy Volunteers

No

Interventions

DRUG

Control Group

Participants in the control group will receive routine clinical care for chronic nonspecific low back pain.

DRUG

Venlafaxine group

Venlafaxine is administered orally at a starting dose of 75 mg once daily. In patients with insufficient pain response who can tolerate the adverse effects, the dose may be carefully titrated up to 225 mg once daily. The maintenance period is 3 months.

Locations (1)

Beijing Tiantan Hospital

Beijing, China, China